Thanks, Guts. Celts and I will not let a few bash
Post# of 7769
Posted On: 03/08/2014 11:40:48 PM
Thanks, Guts. Celts and I will not let a few bashers dissuade us from sharing our positive views on this little gem of a stock.
As a recap for 2013, here is what we know happened through 9/31/13:
FY2013 Q1:
Total Revenues - $287,374
Profit (Loss) from Operations - ($640,268)
Net Profit (Loss) - ($740,992)
E.P.S. - ($0.01)
Total Outstanding Shares - 57,631,739
FY2013 Q2:
Total Revenues - $91,628
Profit (Loss) from Operations - ($2,054,601)
Net Profit (Loss) - ($4,921,176)
E.P.S. - ($0.08)
Total Outstanding Shares - 61,911,747
FY2013 Q3:
Total Revenues - $73,267
Profit (Loss) from Operations - ($2,579,553)
Net Profit (Loss) - ($2,342,626)
E.P.S. - ($0.03)
Total Outstanding Shares - 70,641,911
FY2013 First 9 Months:
Total Revenues - $452,268
Profit (Loss) from Operations - ($6,065,535) ($4.4M non-cash related)
Net Profit (Loss) - ($8,004,796)
E.P.S. - ($0.13)
Here is my SWAG estimate for Q4 and the entire FY2013:
Est. FY2013 Q4:
Total Revenues - $165,500
Profit (Loss) from Operations - ($2,225,000)
Net Profit (Loss) - ($2,500,000)
E.P.S. - ($0.03)
Total Outstanding Shares - 93,000,000
Est. FY2013:
Total Revenues - $617,768
Profit (Loss) from Operations - ($8,290,535)
Net Profit (Loss) - (10,504,796)
E.P.S. - ($0.11)
Total Outstanding Shares - 93,000,000
Remember, my prior post today included my Q1 revenue estimate range between $491K and $594K. Considering the top end of this range does not consider potential revenues from PIMD or RapiMeds Hong Kong, I'd speculate that revenues from merely one of these excluded sources would likely cause Q1 FY14 revenues to eclipse SCRC's total FY13 revenues. That, my friend, would make for an even better start to 2014.
Get those spacesuits ready!
BSAV
As a recap for 2013, here is what we know happened through 9/31/13:
FY2013 Q1:
Total Revenues - $287,374
Profit (Loss) from Operations - ($640,268)
Net Profit (Loss) - ($740,992)
E.P.S. - ($0.01)
Total Outstanding Shares - 57,631,739
FY2013 Q2:
Total Revenues - $91,628
Profit (Loss) from Operations - ($2,054,601)
Net Profit (Loss) - ($4,921,176)
E.P.S. - ($0.08)
Total Outstanding Shares - 61,911,747
FY2013 Q3:
Total Revenues - $73,267
Profit (Loss) from Operations - ($2,579,553)
Net Profit (Loss) - ($2,342,626)
E.P.S. - ($0.03)
Total Outstanding Shares - 70,641,911
FY2013 First 9 Months:
Total Revenues - $452,268
Profit (Loss) from Operations - ($6,065,535) ($4.4M non-cash related)
Net Profit (Loss) - ($8,004,796)
E.P.S. - ($0.13)
Here is my SWAG estimate for Q4 and the entire FY2013:
Est. FY2013 Q4:
Total Revenues - $165,500
Profit (Loss) from Operations - ($2,225,000)
Net Profit (Loss) - ($2,500,000)
E.P.S. - ($0.03)
Total Outstanding Shares - 93,000,000
Est. FY2013:
Total Revenues - $617,768
Profit (Loss) from Operations - ($8,290,535)
Net Profit (Loss) - (10,504,796)
E.P.S. - ($0.11)
Total Outstanding Shares - 93,000,000
Remember, my prior post today included my Q1 revenue estimate range between $491K and $594K. Considering the top end of this range does not consider potential revenues from PIMD or RapiMeds Hong Kong, I'd speculate that revenues from merely one of these excluded sources would likely cause Q1 FY14 revenues to eclipse SCRC's total FY13 revenues. That, my friend, would make for an even better start to 2014.
Get those spacesuits ready!
BSAV
(0)
(0)